BARDA and the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (DoD-JPEO-CBRND) will collaborate with Grifols to make available potentially life-saving COVID-19 treatments that use convalescent plasma or hyperimmune globulin.
Convalescent plasma is a blood product donated by patients that have recovered from COVID-19; the antibodies contained within the donated blood can be used as a treatment for patients still suffering from COVID-19. The antibodies also can be concentrated to produce hyperimmune globulin, a therapeutic product that is more uniform, allows for more flexibility in terms of dosing, and simplifies logistics administering the treatment.
Currently, there are no FDA-approved treatments for COVID-19. New therapeutic treatments, including convalescent plasma and hyperimmune globulin, are urgently needed for patients suffering from COVID-19.
Grifols is currently part of the JPEO-CBRND’s Medical CBRN Development Consortium. BARDA and JPEO-CBRND are partnering through an interagency agreement to support the project, with BARDA providing $12.7 million. With BARDA’s project support, leveraging a separate partnership with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Grifols will collect plasma through a network of more than 250 plasma donor centers in the United States. Grifols then will manufacture both convalescent plasma and hyperimmune globulin ready for clinical use. The products are intended for testing in controlled clinical trials to evaluate their safety and efficacy in treating COVID-19 patients.
This award is one component of BARDA’s Rapidly-Expanding COVID-19 Medical countermeasure portfolio, visit BARDA’s COVID-19 Portfolio to learn more.
The following description is provided by Grifols and does not indicate U.S. government endorsement of the company or its products.
Grifols is a global healthcare company with more than 75 years of history improving the health and well-being of people around the world. We produce essential plasma medicines for patients and provide hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to efficiently deliver expert medical care.
Grifols’ three divisions–Bioscience, Diagnostic, and Hospital–develop, produce, and market innovative products and services available in more than 100 countries.
With the world's largest network of plasma donation centers, the Grifols Bioscience Division is a leading producer of plasma medicines for the treatment of rare, chronic, and sometimes life-threatening conditions. To help ensure a reliable, consistent source of plasma medicines worldwide, Grifols has an all-inclusive process that begins with plasma collection and continues through the fractionation, purification, and production at its three facilities located in Spain (Barcelona) and the United States (Clayton, North Carolina, and Los Angeles, California).
A leader in transfusion medicine, the Grifols Diagnostic Division advances patient care with diagnostic solutions to improve disease detection and management and simplify laboratory operations. The Grifols Hospital Division provides intravenous (IV) therapies, clinical nutrition products, and hospital pharmacy systems, including systems that automate drug compounding and drug inventory control systems.
Headquartered in Barcelona, Grifols employs 20,000 people in 30 countries. Ensuring quality, integrity, and safety in all activities is crucial to our mission, as our products are of vital importance to the health and quality of life of patients we serve.